全文获取类型
收费全文 | 1720篇 |
免费 | 105篇 |
国内免费 | 89篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 25篇 |
妇产科学 | 5篇 |
基础医学 | 292篇 |
口腔科学 | 5篇 |
临床医学 | 176篇 |
内科学 | 401篇 |
皮肤病学 | 8篇 |
神经病学 | 318篇 |
特种医学 | 17篇 |
外科学 | 45篇 |
综合类 | 297篇 |
预防医学 | 99篇 |
眼科学 | 19篇 |
药学 | 150篇 |
中国医学 | 36篇 |
肿瘤学 | 20篇 |
出版年
2024年 | 3篇 |
2023年 | 16篇 |
2022年 | 16篇 |
2021年 | 59篇 |
2020年 | 48篇 |
2019年 | 45篇 |
2018年 | 52篇 |
2017年 | 37篇 |
2016年 | 41篇 |
2015年 | 49篇 |
2014年 | 101篇 |
2013年 | 117篇 |
2012年 | 77篇 |
2011年 | 93篇 |
2010年 | 72篇 |
2009年 | 79篇 |
2008年 | 91篇 |
2007年 | 76篇 |
2006年 | 88篇 |
2005年 | 62篇 |
2004年 | 65篇 |
2003年 | 70篇 |
2002年 | 62篇 |
2001年 | 51篇 |
2000年 | 55篇 |
1999年 | 45篇 |
1998年 | 50篇 |
1997年 | 60篇 |
1996年 | 40篇 |
1995年 | 33篇 |
1994年 | 26篇 |
1993年 | 27篇 |
1992年 | 21篇 |
1991年 | 16篇 |
1990年 | 13篇 |
1989年 | 9篇 |
1988年 | 9篇 |
1987年 | 7篇 |
1986年 | 5篇 |
1985年 | 7篇 |
1984年 | 4篇 |
1983年 | 5篇 |
1982年 | 3篇 |
1981年 | 4篇 |
1980年 | 1篇 |
1979年 | 2篇 |
1978年 | 1篇 |
1977年 | 1篇 |
排序方式: 共有1914条查询结果,搜索用时 31 毫秒
1.
2.
Could non-HDL-cholesterol be a better marker of atherogenic dyslipidemia in obstructive sleep apnea?
《Sleep medicine》2021
Background/objectiveObstructive sleep apnea (OSA) is independently associated with dyslipidemia, a surrogate marker of atherosclerosis. Low-density lipoprotein (LDL)-cholesterol is accepted as a major independent risk factor for cardiovascular disease. However, non-high-density lipoprotein (HDL)-cholesterol is a better marker of atherogenic dyslipidemia and recommended as a target of lipid lowering therapy. We aimed to assess the prevalence of atherogenic dyslipidemia, and relationship between OSA severity and serum LDL-cholesterol and non-HDL cholesterol levels in OSA patients.MethodsWe retrospectively evaluated treatment naïve 2361 subjects admitted to the sleep laboratory of a university hospital for polysomnography. All subjects’ lipid profile including total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, and non-HDL-cholesterol were measured.ResultsOut of 2361 patients (mean age 49.6 ± 11.9 years; 68.9% male, apnea-hypopnea index 36.6 ± 28.4/h), 185 (7.8%) had no OSA and 2176 (92.2%) had OSA. Atherogenic dyslipidemia prevalence was high (57–66%) in OSA patients, and especially increased in severe OSA compared to other groups (p < 0.05). Though total and LDL-cholesterol did not differ between those with and without OSA, non-HDL-cholesterol (p = 0.020), and triglycerides (p = 0.001) were higher and HDL-cholesterol levels (p = 0.018) were lower in OSA patients than non-OSA. Non-HDL-cholesterol was significantly correlated with OSA severity (p < 0.001) and hypoxia parameters (p < 0.01), whereas LDL-cholesterol showed no correlation.ConclusionsAtherogenic dyslipidemia is highly prevalent and non-HDL-cholesterol levels are significantly increased, predominantly in severe OSA patients. Non-HDL-cholesterol but not LDL-cholesterol, is significantly correlated with OSA severity and hypoxia parameters. Therefore, it could be better to use non-HDL-cholesterol, which is a guideline recommended target of lipid therapy, as a marker of atherosclerotic cardiovascular risk in OSA patients. 相似文献
3.
Jonathan Halford Gandis Mazeika Susan Slifer Marcy Speer Ann M Saunders Warren J Strittmatter Joel C Morgenlander 《Movement disorders》2006,21(4):540-542
Ninety-seven inpatients with tardive dyskinesia (average AIMS score = 13), the majority of whom were schizophrenic, were studied. Forty patients were Caucasian, and 57 were African-American. The APOE genotypes of these patients were compared to previously published genotypes of controls and with previously published studies of APOE genotypes in patients with schizophrenia. There were no significant differences in APOE allele frequencies comparing the African-American tardive dyskinesia population and the African-American control groups. In contrast, significant (< 0.05) P values were obtained comparing the Caucasian tardive dyskinesia population to the Caucasian controls, when comparing allele frequencies and genotypic frequencies. This study suggests that Caucasians bearing an APOE2 allele are at increased risk of developing tardive dyskinesia, whereas African-Americans are not. APOE genotype-specific risks of both tardive dyskinesia and Alzheimer's disease that vary across populations could be due to recruitment of patients or controls or could be due to modifying effects of differing genetic or environmental backgrounds. The mechanism by which the APOE2 allele increases risk of tardive dyskinesia is not known. Further information about the mechanisms of increased risk of tardive dyskinesia could result in stratification of prescribing practices weighing the costs of medications against the relative risk of side effects. 相似文献
4.
目的:研究载脂蛋白E(ApoE)基因多态性与颈动脉粥样硬化的相关性。方法:应用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术,对25例B超检测颈动脉内中膜厚度(IMT)增厚患者(增厚组)和25例同期健康体检者(对照组)的ApoE基因多态性进行分析。结果:IMT增厚组ε3等位基因频率较对照组降低(P<0.05),ε4等位基因频率较对照组升高(P<0.01)。IMT增厚组的ε3/ε4基因型频率显著要高于对照组。对以上两组再按ApoE基因型分别分为3组:ApoE2(ε2/2 ε2/3),ApoE3(ε3/3)和ApoE4(ε3/4 ε4/4)。结果显示颈动脉IMT在不同基因型间差异显著,ApoE4组显著增加,颈动脉多发斑块率在此组也显著增加。结论:ApoE基因多态性与颈动脉粥样硬化形成有相关性,ε4基因是颈动脉粥样硬化形成的危险因子。 相似文献
5.
应用聚合酶链反应 限制性片段长度多态性技术 (PCR RFLP) ,以北京自然人群为基础 ,采用分层随机抽样的方法进行横断面研究 ,对 1 0 46人进行apoE基因分型 ,并分析不同特点人群apoE基因频率分布特点。结果表明 :1 )本组人群ε2、ε3、ε4基因频率分别为 9.1 %、81 .2 %和 9.7% ,男女和各年龄组间基因频率无显著差异 ;2 )与欧美国家相比 ,本组人群ε2基因频率增高 ,ε4频率减低 ,与日本人群相比也有相同趋势 ;3 )在空腹血糖受损及糖尿病人群中ε2频率明显增高 ;4)在高胆固醇血症人群中ε2频率减低、ε4基因频率增高 相似文献
6.
7.
测定了30例单纯性肥胖患儿(年龄7岁~12岁)和30例同龄健康儿童的血清载脂蛋白AI(apoAI)、B(apoB)apoB/apoAI比值,甘油三酯(TG)和总胆固醇(TC)。结果肥胖患儿组血清apoAI明显低于健康儿童组,apoB、apoB/apoAI、TG明显高于健康儿童组,差异均非常显著(P<0.01)。肥胖患儿组TC虽然高于健康儿童组,但差异不显著(P>0.05)。 相似文献
8.
Apolipoprotein B polymorphism and altered apolipoprotein B concentrations in Congolese blacks 总被引:1,自引:0,他引:1
Henri-Joseph Parra F. Martin F. Monard N. Ngangoué N. Copin J. M. Bard M. Qafli N. Vu Dac P. Duriez J. C. Fruchart 《Clinical genetics》1991,40(4):263-270
The immunoreactivity of apolipoprotein B (apo B) in plasma obtained from 238 unrelated black African male subjects from the People's Republic of Congo was analysed by non-competitive Enzyme Linked-Immunosorbent Assay (ELISA) with monoclonal BIP 45 anti-LDL antibody. The polymorphism detected by BIP 45 monoclonal antibody is identical to the Ag(c,g) polymorphism. Antibody BIP 45 distinguishes three apo B allotypes (immunophenotypes) encoded by the two allelic genes apo B Ag(c) and apo B Ag(g). Because of co-dominant transmission, genotypes may be inferred from allotypes, and it has been shown that BIP 45 binds strongly to the Ag(c) factor and only weakly to the allelic Ag(g) factor. Analysis of the Congolese plasma samples indicated that 67.65% of them bound BIP 45 with low affinity (Ag(c-,g+) genotype), 28.15% with intermediate affinity (Ag(c+,g+) genotype) and 4.20% with high affinity (Ag(c+,g-) genotype). According to the Hardy-Weinberg equilibrium, this corresponds to gene frequencies of 0.817 and 0.183 for the type Ag(g)/Ag(c) alleles, respectively. After adjustment for age and body-mass index, it was found that the Ag(c) allele decreases the apo B level by 9.62 mg/dl and that the Ag(g) allele increases apo B by 0.43 mg/dl. Therefore, as much as 4.30% of the genetic variance for apo B level could be accounted for by the Ag(c,g) gene locus. 相似文献
9.
本实验用分析基因限制性内切酶片段长度多态性(Restriction fragment length olymorphisms,RFLPs)技术,检测到中国人载脂蛋白AI(Apolipoprotein AI。Apo AI)基因3′端存一PstI多态位点,并发现该多态位点与低高密度脂蛋白(HDL)血症及冠心病有较密切的关系。 相似文献
10.
The neurochemistry of Alzheimer's disease 总被引:1,自引:0,他引:1
Our knowledge of the neurochemical pathology of AD has increased immensely the last years. Although it is now clear that mutations in the APP gene can cause some rare hereditary forms of AD, and that ApoE4 is a prominent risk factor for AD, we at present know little about the underlying cause of AD in the general population and the biochemical mechanisms by which the apolipoprotein E4 isoform affects AD pathogenesis. It is hoped that the near future will see a resolution of the current controversies in AD research, including: 1) whether APP mutations cause Alzheimer's disease by affecting Aβ deposition or the function of APP itself; 2) whether abnormal phosphorylation of tau is a central pathogenetic event, or whether it occurs as epiphenomena that reflect general neurodegeneration in a variety of disease processes; 3) Whether Aβ deposition in the brain is the central event in AD or whether it occurs as epiphenomena in a variety of brain disorders such as head trauma; and 4) whether altered tau phosphorylation occurs secondary to Aβ deposition or vice versa, and what the link is (if any) between the two processes. 相似文献